Inventiva S.A. (IVA): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how a clinical-stage biopharmaceutical company navigates the complex world of drug development? Inventiva S.A. (IVA), a French biotech firm specializing in therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases, stands as a compelling example. With €9.2 million in revenues for the full year of 2024 and significant financial backing, including a first tranche of up to €348 million Structured Financing, how does Inventiva operate and generate revenue in this high-stakes industry? Keep reading to explore Inventiva's history, ownership structure, mission, operational strategies, and revenue generation.

Inventiva S.A. (IVA) History

Founding Timeline

Year established

The company was established in 2012.

Original location

The company is located in Daix, France.

Founding team members

The team consists of experienced executives and scientists with expertise in drug discovery and development.

Initial capital/funding

In 2012, Inventiva secured a €6.3 million ($8.1 million) seed funding round from private investors and Bpifrance, previously known as OSEO.

Evolution Milestones

Transformative Moments

• 2012: Seed Funding: Securing €6.3 million in seed funding from private investors and Bpifrance was crucial for initiating research and development programs.
• 2016: IPO on Euronext Paris: The IPO generated approximately €50 million, providing necessary capital to advance clinical trials for lanifibranor and other pipeline projects.
• 2017: Positive Phase IIb Results for Lanifibranor: Positive results in Phase IIb clinical trials for NASH propelled further development and increased investor confidence.
• 2020: Phase III Clinical Trials for Lanifibranor: Entering Phase III clinical trials marked a critical stage in the development of lanifibranor, potentially leading to a breakthrough treatment for NASH.
• Strategic Partnerships: Forming collaborations with other pharmaceutical companies and research institutions enhanced capabilities and expanded the scope of research.

To gain more insights into the investors behind this company, check out this detailed profile: Exploring Inventiva S.A. (IVA) Investor Profile: Who’s Buying and Why?

Inventiva S.A. (IVA) Ownership Structure

Inventiva S.A. features a mixed ownership structure, comprising both public shareholders and institutional investors, influencing its corporate governance and strategic direction.

Inventiva S.A.'s Current Status

Inventiva S.A. is a publicly traded company, listed on the Euronext Paris stock exchange under the ticker symbol IVA. As a public entity, it is subject to regulatory oversight and reporting requirements, ensuring transparency for its shareholders and the public.

Inventiva S.A.'s Ownership Breakdown

The ownership of Inventiva S.A. is distributed among various shareholders, including institutional investors, individual shareholders, and potentially company insiders. The following table provides an overview of the estimated ownership breakdown:

Inventiva S.A.'s Leadership

The leadership team is responsible for the strategic direction and operational management of Inventiva S.A.

• Frédéric Cren serves as the Chief Executive Officer.
• Jean-Louis Abitbol is the Chief Medical Officer.
• Pierre Broqua holds the position of Chief Scientific Officer.

These individuals, along with other key executives, guide the company's efforts in drug development and corporate strategy. More information about Inventiva S.A.'s financial standing can be found at: Breaking Down Inventiva S.A. (IVA) Financial Health: Key Insights for Investors

Inventiva S.A. (IVA) Mission and Values

Inventiva S.A. focuses on developing innovative therapies for diseases with significant unmet medical needs, particularly in the areas of metabolic diseases, fibrosis, and liver diseases. Their core values revolve around scientific excellence, patient-centricity, and a commitment to improving healthcare outcomes.

Inventiva S.A.'s Core Purpose

Official mission statement

While a direct, concise mission statement for Inventiva S.A. isn't explicitly available in recent search results, we can infer their mission from their activities and focus. The mission can be understood as:

To develop and commercialize innovative therapies addressing significant unmet needs in metabolic diseases, fibrosis, and other areas with high medical need, thereby improving the lives of patients worldwide.

• Inventiva is dedicated to the discovery and development of new therapeutic options for patients suffering from chronic diseases.
• The company places a strong emphasis on scientific rigor and innovation in its research and development efforts.
• A core component of their mission involves strategic partnerships to expand their reach and accelerate the development and commercialization of their drug candidates.

Vision statement

Similarly, a specific vision statement isn't readily available. However, based on Inventiva's strategic goals, a vision statement can be formulated as:

To be a leading biopharmaceutical company recognized for its innovative therapies and commitment to transforming the treatment landscape for patients with metabolic diseases, fibrosis, and liver disorders.

• Inventiva aspires to be at the forefront of innovation in the treatment of metabolic and fibrotic diseases.
• The company aims to deliver significant value to patients, healthcare providers, and shareholders through the successful development and commercialization of its drug pipeline.
• Inventiva seeks to establish itself as a trusted partner in the healthcare community, known for its scientific expertise and dedication to improving patient outcomes.

Company slogan/tagline

There is no readily available official slogan or tagline for Inventiva S.A. A possible tagline that reflects their mission and vision could be:

Inventiva: Innovating for a Healthier Future.

For more insights into Inventiva S.A., explore Exploring Inventiva S.A. (IVA) Investor Profile: Who’s Buying and Why?

Inventiva S.A. (IVA) How It Works

Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs.

Inventiva's Product/Service Portfolio

Inventiva's Operational Framework

Inventiva operates as a research and development company, primarily focused on advancing its drug candidates through clinical trials. Key aspects of their operational framework include:

• Research and Development: Conducting preclinical and clinical studies to evaluate the safety and efficacy of their drug candidates.
• Clinical Trials: Managing and executing clinical trials across various geographies, adhering to regulatory standards.
• Partnerships: Collaborating with other pharmaceutical companies and research institutions to accelerate drug development and expand their pipeline.
• Regulatory Affairs: Working with regulatory agencies such as the FDA and EMA to obtain marketing approvals for their products.
• Manufacturing: Overseeing the manufacturing process of their drug candidates, either through in-house facilities or partnerships with contract manufacturing organizations (CMOs).

Inventiva's Strategic Advantages

Inventiva's strategic advantages in the biopharmaceutical industry include:

• Innovative Pipeline: A portfolio of drug candidates targeting significant unmet medical needs with potential for breakthrough therapies.
• Scientific Expertise: A team of experienced scientists and drug developers with a strong track record in discovering and developing novel therapeutics.
• Strategic Partnerships: Collaborations with leading pharmaceutical companies and research institutions to leverage resources and expertise.
• Intellectual Property: A strong patent portfolio protecting their drug candidates and technologies.
• Focus on NASH: Lanifibranor is designed to simultaneously target three PPAR isoforms (alpha, delta, and gamma) to modulate multiple pathways involved in NASH.

To gain more insights into Inventiva S.A., consider reading this comprehensive investor profile: Exploring Inventiva S.A. (IVA) Investor Profile: Who’s Buying and Why?

Inventiva S.A. (IVA) How It Makes Money

Inventiva S.A., a biopharmaceutical company, primarily generates revenue through the development and commercialization of innovative therapies, focusing on treatments for nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs.

Inventiva S.A.'s Revenue Breakdown

As a clinical-stage biopharmaceutical company, Inventiva S.A.'s revenue streams are primarily influenced by research collaborations, licensing agreements, and milestone payments. As of the fiscal year 2024, the detailed breakdown is not explicitly available in the provided search results. Nonetheless, a generalized structure can be inferred based on typical biotech revenue models.

Inventiva S.A.'s Business Economics

Inventiva S.A.'s business economics are characterized by substantial investment in research and development (R&D), typical of a biotech firm. Key aspects include:

• R&D Expenditure: A significant portion of operating expenses is allocated to R&D, reflecting the company's focus on drug development.
• Clinical Trial Costs: Expenses associated with clinical trials represent a major cost driver.
• Intellectual Property: Protecting its drug candidates through patents is crucial for maintaining a competitive advantage and future revenue streams.

Understanding Inventiva S.A.'s mission and vision provides additional context to their strategic approach; you can explore more at Mission Statement, Vision, & Core Values of Inventiva S.A. (IVA).

Inventiva S.A.'s Financial Performance

Analyzing Inventiva S.A.'s financial performance involves assessing key metrics that reflect its operational efficiency and financial health. Given the information available up to April 2025, here are some typical considerations for a biopharmaceutical company like Inventiva S.A.:

• Cash Reserves: Monitoring cash and cash equivalents is vital to ensure the company can fund ongoing operations and R&D activities.
• Operating Expenses: Evaluating operating expenses, particularly R&D and administrative costs, provides insights into how efficiently the company manages its resources.
• Net Loss: As a development-stage company, Inventiva S.A. typically reports a net loss, which is expected to decrease as products move closer to commercialization.

As of the fiscal year 2024, detailed financial figures would offer a more precise understanding of Inventiva S.A.'s financial status, but the above points provide a general framework for evaluation.

Inventiva S.A. (IVA) Market Position & Future Outlook

As of April 2025, Inventiva S.A. is navigating a complex pharmaceutical landscape, striving to solidify its position in the treatment of metabolic diseases, particularly NASH. The company's future hinges on the successful development and commercialization of its drug candidates and strategic partnerships.

Competitive Landscape

The competitive landscape for Inventiva S.A. is shaped by other pharmaceutical companies focusing on metabolic diseases and NASH. Below is a hypothetical representation of the market share and key advantages of some key players as of the fiscal year 2024:

Opportunities & Challenges

Inventiva S.A. faces both opportunities and risks that could significantly impact its future performance.

Industry Position

Inventiva S.A. is a pharmaceutical company specializing in the development of therapies for metabolic diseases, with a primary focus on NASH. Here are key aspects of its industry position:

• NASH Focus: The company's lead drug candidate, lanifibranor, targets NASH, a significant and growing market with limited treatment options.
• Pipeline: Inventiva S.A. has a pipeline of drug candidates in various stages of development, addressing different aspects of metabolic diseases.
• Partnerships: Strategic collaborations with other companies can provide financial resources, expertise, and market access.
• Innovation: Inventiva S.A. aims to differentiate itself through innovative drug development and unique mechanisms of action.

For more insights into Inventiva S.A.'s financial health, you can explore: Breaking Down Inventiva S.A. (IVA) Financial Health: Key Insights for Investors